Understanding the genetic alterations that lead to lymphoma/cll cancer is essential to fighting the disease. At Fox Chase, a multidisciplinary team of researchers and clinicians meets regularly to review translational research initiatives to identify and characterize new biomarkers of lymphoma/cll cancer that lead to new, innovative prevention and targeted therapy options for our patients.
-
Faculty Group Members
-
Tahseen I. Al-Saleem, MD
-
Siddharth Balachandran, PhD
-
Kerry S. Campbell, PhD
-
Henry Chi Hang Fung, MD, FACP, FRCPE
-
Mark A. Hallman, MD, PhD
-
Kyoko Hayakawa, MD, PhD
-
Jian Huang, MD, PhD
-
Dietmar J. Kappes, PhD
-
Warren D. Kruger, PhD
-
Eric A. Ross, PhD, ScM
-
Joseph R. Testa, PhD, FACMG
-
David Wiest, PhD
-
Yibin Yang, PhD
-
-
Research Faculty
Clinical and research fellows are welcome to attend this TRDG meeting. Also, any faculty who have an interest in participation please communicate with Alison Conn.
-
Funding Opportunities
Support for our research initiatives allows Fox Chase to have a continued stake in the future of translational research, and the Center encourages our researchers and clinician to apply for grant funding to advance the mission to prevail over cancer. Below is a list of current research funding opportunities:
NCI Clinical and Translation Exploratory/Development Studies (R21)
-
Giving
As a nonprofit institution, support from donors allows Fox Chase to remain one of the top cancer research and treatment centers in the country. Through donations, planned gifts, and membership to our giving societies, our supporters ensure Fox Chase remains at the forefront of lymphoma/cll cancer research and novel treatment options that save lives.
To give to the lymphoma/cll cancer research program, visit foxchase.org/giving.
